Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease

Key Takeaways BAYRY has started a phase I/IIa study of OpCT-001 for primary photoreceptor degenerative diseases. OpCT-001 is the first iPSC-derived cell therapy tested in humans for inherited eye conditions. The CLARICO trial assesses safety, vision impact, and cell engraftment across patient subgroups.Bayer’s (BAYRY) wholly owned subsidiary, BlueRock Therapeutics, announced that the first patient in the phase I/IIa CLARICO study has received OpCT-001, an investigational iPSC-derived cell therapy, which i ...